BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29685813)

  • 1. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.
    Ratjen F; Moeller A; McKinney ML; Asherova I; Alon N; Maykut R; Angyalosi G;
    J Cyst Fibros; 2019 Jan; 18(1):78-85. PubMed ID: 29685813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
    Wiesemann HG; Steinkamp G; Ratjen F; Bauernfeind A; Przyklenk B; Döring G; von der Hardt H
    Pediatr Pulmonol; 1998 Feb; 25(2):88-92. PubMed ID: 9516091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.
    Blanchard AC; Rooney AM; Yau Y; Zhang Y; Stapleton PJ; Horton E; Klingel M; Stanojevic S; Ratjen F; Coburn B; Waters V
    J Cyst Fibros; 2018 Nov; 17(6):723-728. PubMed ID: 29525410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
    Mayer-Hamblett N; Retsch-Bogart G; Kloster M; Accurso F; Rosenfeld M; Albers G; Black P; Brown P; Cairns A; Davis SD; Graff GR; Kerby GS; Orenstein D; Buckingham R; Ramsey BW;
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1177-1187. PubMed ID: 29890086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
    Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
    Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
    LeLorier J; Perreault S; Birnbaum H; Greenberg P; Sheehy O
    Clin Ther; 2000 Jan; 22(1):140-51. PubMed ID: 10688397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Van Stormbroek B; Zampoli M; Morrow BM
    Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.